- Home
- DFP vs CRMD Comparison
DFP vs CRMD Comparison
Compare DFP & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFP
- CRMD
- Stock Information
- Founded
- DFP 2013
- CRMD 2006
- Country
- DFP United States
- CRMD United States
- Employees
- DFP N/A
- CRMD N/A
- Industry
- DFP Investment Managers
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- DFP Finance
- CRMD Health Care
- Exchange
- DFP Nasdaq
- CRMD Nasdaq
- Market Cap
- DFP 396.2M
- CRMD 464.7M
- IPO Year
- DFP N/A
- CRMD 2010
- Fundamental
- Price
- DFP $20.07
- CRMD $11.66
- Analyst Decision
- DFP
- CRMD Strong Buy
- Analyst Count
- DFP 0
- CRMD 6
- Target Price
- DFP N/A
- CRMD $15.00
- AVG Volume (30 Days)
- DFP 56.2K
- CRMD 2.2M
- Earning Date
- DFP 01-01-0001
- CRMD 05-06-2025
- Dividend Yield
- DFP 6.73%
- CRMD N/A
- EPS Growth
- DFP N/A
- CRMD N/A
- EPS
- DFP N/A
- CRMD 0.28
- Revenue
- DFP N/A
- CRMD $82,553,827.00
- Revenue This Year
- DFP N/A
- CRMD $207.65
- Revenue Next Year
- DFP N/A
- CRMD $50.13
- P/E Ratio
- DFP N/A
- CRMD $42.08
- Revenue Growth
- DFP N/A
- CRMD N/A
- 52 Week Low
- DFP $15.45
- CRMD $3.61
- 52 Week High
- DFP $19.31
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- DFP 58.87
- CRMD 71.85
- Support Level
- DFP $19.89
- CRMD $8.72
- Resistance Level
- DFP $20.12
- CRMD $9.82
- Average True Range (ATR)
- DFP 0.21
- CRMD 0.67
- MACD
- DFP 0.09
- CRMD 0.40
- Stochastic Oscillator
- DFP 91.22
- CRMD 84.78
About DFP Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.
Flaherty & Crumrine Dynamic Preferred and Income Fund Inc is a diversified, closed-end management investment company. Its investment objective is to seek total return, with an emphasis on high current income.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.